HOME >> BIOLOGY >> NEWS
Effectiveness of certain antidepressants may be influenced by gene variations of individuals

Whether specific types of antidepressants are effective for patients with late-life major depression may depend if they have certain genetic variations, according to a study in the October 4 issue of JAMA.

Initial drug treatments fail in 30 percent to 40 percent of patients with major depression. Pharmacogenetic (the relation of genetic factors to variations in response to drugs) prediction of response is one possibility for improving antidepressant treatment, according to background information in the article. Polymorphisms (occurrence in more than one form) in the serotonin transporter gene (5-HTT) may influence antidepressant response to selective serotonin reuptake inhibitors (SSRIs a class of antidepressant drugs).

Hyeran Kim, M.D., of Sungkyunkwan University School of Medicine, Seoul, Korea, and colleagues conducted a study to determine whether there were significant associations between the efficacy of norepinephrine reuptake inhibitors (NRIs - a class of antidepressant drugs) and norepinephrine transporter (NET) polymorphisms and also between SSRI efficacy and 5-HTT polymorphisms. If confirmed, these associations could provide a basis for predicting response to certain antidepressants. The study included 241 Korean patients with major depression. They were treated for 6 weeks with an SSRI (fluoxetine or sertraline; n = 136) or an NRI (nortriptyline; n = 105) antidepressant. The average age at onset of major depressive disorder among these patients was in the early to mid-50s.

The researchers found that the presence of certain polymorphisms, alone or in combination, was associated with response and non-response to therapy with SSRIs or NRIs.

They write that their data analysis suggests that patients carrying the GG polymorphism of NET G1287A have a statistically significantly superior rate of response to NRI treatment than to SSRI treatment (83.3 percent vs. 58.7 percent).

" this study demonstrates that the
'"/>

Contact: Doh Kwan Kim
paulkim@smc.samsung.co.kr
JAMA and Archives Journals
3-Oct-2006


Page: 1 2

Related biology news :

1. Aggressive therapy best for certain AML patients
2. Study examines cause of hearing loss for patients with certain genetic disease
3. Endometriosis increases the risk of certain cancers
4. NJIT professor says certain home shapes and roofs hold up best in hurricane
5. Researchers discover acquired DNA key to certain bacterial infection
6. Nutrients in certain vegetables may provide cancer-fighting benefit
7. Study fails to verify gene variations as risk factors for certain cardiovascular problems
8. Genetic analyis for personalizing of treatment of lung and colon cancer, certain sarcomas
9. Male fish turn to cannibalism when uncertain of paternity
10. Diet can provide protection against development of certain cancers, new studies show
11. Firefighters face increased risk for certain cancers

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... ... July 01, 2020 , ... Catalent, ... the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga ... supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers with ...
(Date:6/28/2020)... ... June 25, 2020 , ... In an upcoming episode ... in accelerated Point of Care Testing solutions (POCT). Check local listings for more info. ... at medical offices and are shipped to labs throughout the country. Results are then ...
(Date:6/23/2020)... ... June 23, 2020 , ... First ... Renovagen Ltd, a UK supplier and manufacturer of innovative portable renewable energy equipment, ... in the fight against the COVID-19 pandemic in Zambia. , One of Renovagen’s ...
Breaking Biology News(10 mins):
(Date:7/18/2020)... ... , ... “We are thrilled to deliver this new technology to the industry” ... kind on the market and we were pleased that the IFT jury recognized that.” ... ingredients, creating a natural way to extend the shelf life and improve the safety ...
(Date:7/18/2020)... ... July 17, 2020 , ... ... firm for the life sciences and food industries, is pleased to announce that ... Clinical Research – Business Development. , Charles is an accomplished and results-driven sales ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... Technology (MIT) has expanded the company’s exclusive license to include clinical applications ... point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage ... Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. Dr. Nissenson ... product, SBI-101. Dr. Nissenson serves as an Emeritus Professor of Medicine at ...
Breaking Biology Technology:
Cached News: